1
|
Lutz V, Chidiak M, Frouin R, Negri R, Dogliotti AI, Santamaria-Del-Angel E, Berghoff CF, Rojas J, Filipello C, Astor Y, Segura V, Gonzalez-Silvera A, Escudero L, Ledesma J, Ueyoshi K, Silva RI, Ruiz MG, Cozzolino E, Allega L, Tan J, Kampel M. Regulation of CO 2 by the sea in areas around Latin America in a context of climate change. Environ Monit Assess 2023; 195:417. [PMID: 36807829 DOI: 10.1007/s10661-023-10997-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Accepted: 01/28/2023] [Indexed: 06/18/2023]
Abstract
Anthropogenic activities are increasing the atmospheric carbon dioxide (CO2); around a third of the CO2 emitted by these activities has been taken up by the ocean. Nevertheless, this marine ecosystem service of regulation remains largely invisible to society, and not enough is known about regional differences and trends in sea-air CO2 fluxes (FCO2), especially in the Southern Hemisphere. The objectives of this work were as follows: first to put values of FCO2 integrated over the exclusive economic zones (EEZ) of five Latin-American countries (Argentina, Brazil, Mexico, Peru, and Venezuela) into perspective regarding total country-level greenhouse gases (GHG) emissions. Second, to assess the variability of two main biological factors affecting FCO2 at marine ecological time series (METS) in these areas. FCO2 over the EEZs were estimated using the NEMO model, and GHG emissions were taken from reports to the UN Framework Convention on Climate Change. For each METS, the variability in phytoplankton biomass (indexed by chlorophyll-a concentration, Chla) and abundance of different cell sizes (phy-size) were analyzed at two time periods (2000-2015 and 2007-2015). Estimates of FCO2 at the analyzed EEZs showed high variability among each other and non-negligible values in the context of greenhouse gas emissions. The trends observed at the METS indicated, in some cases, an increase in Chla (e.g., EPEA-Argentina) and a decrease in others (e.g., IMARPE-Peru). Evidence of increasing populations of small size-phytoplankton was observed (e.g., EPEA-Argentina, Ensenada-Mexico), which would affect the carbon export to the deep ocean. These results highlight the relevance of ocean health and its ecosystem service of regulation when discussing carbon net emissions and budgets.
Collapse
Affiliation(s)
- V Lutz
- CONICET-INIDEP, 7600, Mar del Plata, Argentina.
- Instituto Nacional de Investigación y Desarrollo Pesquero (INIDEP), 7600, Mar del Plata, Argentina.
| | - M Chidiak
- Facultad de Ciencias Económicas, Instituto Interdisciplinario de Economía Política, Universidad de Buenos Aires, C1120AAQ, Buenos Aires, Argentina
| | - R Frouin
- Scripps Institution of Oceanography, University of California San Diego, 8810 Shellback Way, La Jolla, San Diego, CA, 92037, USA
| | - R Negri
- Instituto Nacional de Investigación y Desarrollo Pesquero (INIDEP), 7600, Mar del Plata, Argentina
| | - A I Dogliotti
- Instituto de Astronomía Y Física del Espacio (IAFE), Pabellón IAFE, CONICET-Universidad de Buenos Aires, Ciudad Universitaria, Ciudad Autónoma de Buenos Aires C1428ZAA, Buenos Aires, Argentina
- Instituto Franco-Argentino Para El Estudio del Clima Y Sus Impactos (UMI-IFAECI, CNRSCONICET-UBA), C1428EGA, Buenos Aires, Argentina
| | - E Santamaria-Del-Angel
- Facultad de Ciencias Marinas, Universidad Autónoma de Baja California, 22860, Ensenada, México
| | - C F Berghoff
- Instituto Nacional de Investigación y Desarrollo Pesquero (INIDEP), 7600, Mar del Plata, Argentina
| | - J Rojas
- Fundación La Salle de Ciencias Naturales Campus Margarita (EDIMAR), Isla Margarita, Venezuela
| | - C Filipello
- Facultad de Ciencias Económicas, Instituto Interdisciplinario de Economía Política, Universidad de Buenos Aires, C1120AAQ, Buenos Aires, Argentina
| | - Y Astor
- Fundación La Salle de Ciencias Naturales Campus Margarita (EDIMAR), Isla Margarita, Venezuela
| | - V Segura
- Instituto Nacional de Investigación y Desarrollo Pesquero (INIDEP), 7600, Mar del Plata, Argentina
| | - A Gonzalez-Silvera
- Facultad de Ciencias Marinas, Universidad Autónoma de Baja California, 22860, Ensenada, México
| | - L Escudero
- Instituto del Mar del Perú, 07021, Callao, Perú
| | - J Ledesma
- Instituto del Mar del Perú, 07021, Callao, Perú
| | - K Ueyoshi
- Scripps Institution of Oceanography, University of California San Diego, 8810 Shellback Way, La Jolla, San Diego, CA, 92037, USA
| | - R I Silva
- Instituto Nacional de Investigación y Desarrollo Pesquero (INIDEP), 7600, Mar del Plata, Argentina
| | - M G Ruiz
- Instituto Nacional de Investigación y Desarrollo Pesquero (INIDEP), 7600, Mar del Plata, Argentina
| | - E Cozzolino
- Instituto Nacional de Investigación y Desarrollo Pesquero (INIDEP), 7600, Mar del Plata, Argentina
| | - L Allega
- Instituto Nacional de Investigación y Desarrollo Pesquero (INIDEP), 7600, Mar del Plata, Argentina
| | - J Tan
- Scripps Institution of Oceanography, University of California San Diego, 8810 Shellback Way, La Jolla, San Diego, CA, 92037, USA
| | - M Kampel
- Instituto Nacional de Pesquisas Espaciais, Sao Jose Dos Campos, 12227-010, Brazil
| |
Collapse
|
2
|
Marti Pi M, Gascon Ruiz M, Casas-Deza D, Torres Ramon I, Zapata-Garcia M, Sesma A, Lambea- Sorrosal JJ, Alvarez M, Quilez E, Zurera Berjaga M, Moratiel Pellitero A, Ruiz Moreno I, Goas Gomez A, Isla D, Arbonés-Mainar JM. Diagnosis of malnutrition according to glim criteria predicts complications and six-month survival in cancer outpatients. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e24093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e24093 Background: Malnutrition is a condition with great impact in oncology patients. Poor nutritional status is often associated with increased morbidity and mortality, increased toxicity and reduced tolerance to chemotherapy, among other complications. The recent GLIM criteria for malnutrition aim to homogenize its diagnosis, considering the baseline disease status. Due to the few studies that assess the predictive capacity of these new criteria, we aimed to evaluate their performance for the prediction of complications and mortality in patients with cancer. Methods: Prospective, single-centre study. All outpatients under active treatment for head and neck, upper gastrointestinal and colorectal tumors between February and October 2020 were recruited. These patients were followed up for 6 months, assessing the occurrence of complications and survival, based on GLIM diagnosis of malnutrition. Results: We enrolled 165 outpatients 46.66% malnutrition. During 6-month follow-up, patients with malnutrition (46.7%, according to GLIM criteria) had an ̃3-fold increased risk of hospital admission (p < 0.001) and the occurrence of severe infections (considered as such those requiring hospitalization, intravenous antibiotics and/or drainage by interventional procedure) during follow-up (p = 0.002). Similarly, malnourished patients had a 3.5-fold increased risk of poor pain control and a 4.4-fold increased need for a higher dose of opioids (both p < 0.001). They also had a 2.6-fold increased risk of toxicity (p = 0.044) and a 2.5-fold increased likelihood of needing a dose decrease or discontinuation of cancer treatment (p = 0.011). 6-month survival of malnourished patients was significantly lower (p = 0.023) than non-malnourished patients. Conclusions: Diagnosis of malnutrition according to GLIM criteria in oncology patients on active treatment predicts increased complications and worse survival at 6-month follow-up, making them a useful tool to assess the nutritional status of oncology patients.[Table: see text]
Collapse
Affiliation(s)
- Maria Marti Pi
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Marta Gascon Ruiz
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Diego Casas-Deza
- Gastroenterology department Hospital Miguel Servet Zaragoza, Zaragoza, Spain
| | | | - Maria Zapata-Garcia
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Andrea Sesma
- Department of Medical Oncology, Clinico Lozano Blesa University Hospital, Zaragoza, Spain
| | | | - Maria Alvarez
- Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Elisa Quilez
- Department of Medical Oncology, Hospital Clínico Lozano Blesa, Zaragoza, Spain
| | | | | | - Ines Ruiz Moreno
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Ana Goas Gomez
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | | | | |
Collapse
|
3
|
Moratiel Pellitero A, Ruiz Moreno I, Cruellas M, Alonso Marin N, Ocáriz M, Gascon Ruiz M, Sesma Goñi A, Zapata-Garcia M, Zurera Berjaga M, Marti Pi M, Goas Gomez A, Camacho Fuentes C, Sanchez Cortes C, Alvarez M, Quilez E, Torres I, Lambea- Sorrosal JJ, Isla D, Lastra R. Surrogates of response to treatment of non-small cell lung cancer with immunotherapy: Toxicity and leukocyte ratios—Experience of a center. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e21052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21052 Background: Immunotherapy is proposed as a therapeutic novelty in metastatic non-small cell lung cancer (NSCLC), in many cases already in front line. It presents different adverse effects than traditional schemes, due to the stimulation of the immune system. There is a possible relationship between toxicity and response. Neutrophil-to-lymphocyte ratio (NLR) as a possible predictive factor of response. Objectives: Evaluating the response according to the toxicity degree in NSCLC patients in real clinical practice. Analyze whether pretreatment NLR high patients have a worse prognosis. Methods: Observational, retrospective, analytical, single-center study. HCULB stage IV NSCLC patients with inmunotherapy treatment during 2016-2018. Descriptive and multivariate analysis. Toxicity grade: CTCAE version 4.0. Response assessment: RECIST 2.0 and immunorelated criteria. Toxicity degree and response (global and individualized results according to treatment and histology). Neutrophil-to-lymphocyte ratio and response. Results: N = 43 patients (35 men, 8 women). Average age 64 years. Response: 3 complete response (CR) (toxicity ≥2), 13 partial response (PR) (toxicity ≥1), 13 stable disease (SD), 12 progression (P) (only 4 toxicity and ≤2), 2 not evaluated. Hypothyroidism as the most common irAE. Relationship between toxicity and response: the absence of irAEs conditions worse prognosis p < 0.05. Histology: 25 adenocarcinoma [18 with irAES (1 CR, 7 PR, 8 SD,) and 7 without (1 SD, 5 P, 1 no ev.)]; 17 squamous [13 with irAES (1 CR, 6 PR, 4 SD) and 4 without (3 P, 1 no ev.)]; 1 adenosquamous with irAES and CR. Drug: Atezolizumab N = 8 [6 with irAES (2 PR, 3 SD, 1 P) and 2 without (both P)], Nivolumab N = 16 [9 with irAES (1 CR, 3 PR, 3 SD, 2 P) and 7 without (1 SD, 4 P, 2 no ev.)], Pembrolizumab N = 19 [17 with irAEs (2 CR, 8 PR, 6 SD, 1 P) and 2 without (both P)]. Significant positive correlation between toxicity and response (p < 0.001) R = 0.067, (CI 99% 0.378-0.837), regardless of histology and drug. It is observed a better response in those patients who presented a NRL close to 3 or less at the beginning of treatment. On the contrary, it is observed that subjects with NRL greater than 4 obtained worse results when they were treated with immunotherapy. Conclusions: The appearance of irAES like a response indicator of immune system, seem to conditione better evolution. In contrast, the absence of toxicity predicts a worse prognosis. Further studies with a larger sample are needed to confirm our findings about the predictive value of NLR and optimize therapeutic regimens if necessary.
Collapse
Affiliation(s)
| | - Ines Ruiz Moreno
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Mara Cruellas
- Medical Oncology Department, University Hospital Vall d´Hebron and Vall d´Hebron Institute of Oncology, Barcelona, Spain
| | | | - Maitane Ocáriz
- Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Marta Gascon Ruiz
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Andrea Sesma Goñi
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Maria Zapata-Garcia
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | | | - Maria Marti Pi
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Ana Goas Gomez
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | | | | | - Maria Alvarez
- Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Elisa Quilez
- Department of Medical Oncology, Hospital Clínico Lozano Blesa, Zaragoza, Spain
| | - Irene Torres
- Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain
| | | | | | - Rodrigo Lastra
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| |
Collapse
|
4
|
Gascon Ruiz M, Casas-Deza D, Torres I, Zapata-Garcia M, Alonso Marin N, Sesma Goñi A, Lambea- Sorrosal JJ, Alvarez M, Quilez E, Zurera Berjaga M, Ocáriz M, Moratiel Pellitero A, Ruiz Moreno I, Goas Gomez A, Marti Pi M, Arbonés-Mainar JM, Isla D. GLIM versus ESPEN criteria for the diagnosis of early malnutrition in oncological outpatients. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e24065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e24065 Background: Malnutrition is one of the most prevalent problems among oncological patients. It reduces the response to treatments and negatively impacts survival. In 2019, a consensus criteria for diagnosing malnutrition (GLIM criteria) were proposed by most scientific nutrition societies. The objective of our work is 1) to assess the diagnostic capacity of the GLIM criteria in ambulatory patients with cancer and 2) to compare the GLIM with the ESPEN criteria to evaluate the contributions of these new criteria with respect to the existing ones. Methods: Observational, cross-sectional, and single-center study carried out at the Medical Oncology Department in the Lozano Blesa Clinical Hospital in Zaragoza (Spain). One hundred and sixty-five outpatients with tumors in the upper gastrointestinal tract, head and neck, and colorectal locations were recruited. All of them received the MST, MUST, and Nutriscore screening tools along with the ESPEN and GLIM diagnostic criteria. Results: The prevalence of malnutrition was 46.7% according to the GLIM criteria and 21.2% using the ESPEN tool. Patients diagnosed by GLIM had a higher body mass index (BMI, 24.3 kg/m2) and muscle mass (MM, 16.1 kg/m2) than those diagnosed by ESPEN (21.2 kg/m² and 14.3 kg/m2 respectively, both p = 0.001). The MST, MUST, and Nutriscore tools had a higher degree of concordance with GLIM compared to ESPEN (MST 0.53 vs 0.26; MUST 0.36 vs 0.66; Nutriscore 0.28 vs 0.54). Conclusions: The found prevalence of malnutrition in cancer patients is higher using the GLIM instead of ESPEN criteria. This disparity can be explained at least in part by the difficulty of the ESPEN criteria for malnutrition to diagnose patients with high baseline BMI or MM. The use of criteria with greater sensitivity, such as the new GLIM criteria, could help early diagnosis and thus early intervention in cancer patients. [Table: see text]
Collapse
Affiliation(s)
- Marta Gascon Ruiz
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Diego Casas-Deza
- Gastroenterology department Hospital Miguel Servet Zaragoza, Zaragoza, Spain
| | - Irene Torres
- Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain
| | - Maria Zapata-Garcia
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | | | - Andrea Sesma Goñi
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | | | - Maria Alvarez
- Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Elisa Quilez
- Department of Medical Oncology, Hospital Clínico Lozano Blesa, Zaragoza, Spain
| | | | - Maitane Ocáriz
- Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | | | - Ines Ruiz Moreno
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Ana Goas Gomez
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Maria Marti Pi
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | | | | |
Collapse
|
5
|
Alonso Marin N, Ocáriz M, Gascon Ruiz M, Sesma Goñi A, Zurera Berjaga M, Zapata-Garcia M, Ruiz Moreno I, Moratiel Pellitero A, Marti Pi M, Goas Gomez A, Cruellas M, Alvarez M, Andrés R, Isla D, Lastra R. Hereditary breast cancer associated with the CHEK2 gene: Study through NGS in a Spanish cohort. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e22502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22502 Background: Inherited mutations in the CHEK2 gene have been associated with an increased lifetimerisk of develop breast cancer (BC). The main objective of the study is to identify in our population the prevalence of mutations in the CHEK2 gene in diagnosed BC patients, as well as to evaluate the phenotypic characteristics of the tumour and family history. Methods: A genetic study was performed in 396 patients diagnosed of BC at the University Hospital Lozano Blesa of Zaragoza (Spain). We selected 9 patients with genetic variants in the CHEK2 gene and performed a descriptive analysis of the clinical variables, a bibliographic review of the genetic variants and a co-segregation study. Results: We identified 2 pathogenic variants ( CHEK2 c.349 A>G and c.507delT) and 6 variants of uncertain significance (VUS). The genotypic characteristics of the VUS are summarized in the table. In all cases there was a family history of BC in first and /or second degree relatives. The variant cosegregated with the disease in one of the families. Conclusions: The pathogenic missense variant c.349A>G was found in two families. This is a rare missense variant. Studies have shown that this variant had a significant impact on the protein based on in silico prediction and has been associated with BC. In our study, this variant was found in a patient with renal carcinoma and was identified in a proband with a strong family history of pancreatic and ovarian cancer (OC). However, there aren’t exist data about the risk of developing other cancer, different of BC, with this specific mutation. The other pathogenic variant detected was CHEK2 c.507delT in a family with history of BC and OC. This variant is a frameshift mutation, predicted to cause loss of normal protein function. CHEK2 507delT was reported in one of 12 BC families in one series and is possible its relation with OC. With regard to the VUS the cosegregation analysis in selected families may help understand if a variant could have played a role in developing cancer. In conclusion, CHEK2 mutations have been associated with increased risk for BC. However, the frequency of carriers may vary depending on the population, and different mutations may be associated with different cancer risks. More studies are needed to establish a complete range of risks associated with CHEK2 mutations. [Table: see text]
Collapse
Affiliation(s)
| | - Maitane Ocáriz
- Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Marta Gascon Ruiz
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Andrea Sesma Goñi
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | | | - Maria Zapata-Garcia
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Ines Ruiz Moreno
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | | | - Maria Marti Pi
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Ana Goas Gomez
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Mara Cruellas
- Medical Oncology Department, University Hospital Vall d´Hebron and Vall d´Hebron Institute of Oncology, Barcelona, Spain
| | - Maria Alvarez
- Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Raquel Andrés
- Hospital Clínico Universitario Lozano Blesa, Zaragoza, Zaragoza, Spain
| | | | - Rodrigo Lastra
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| |
Collapse
|
6
|
Zapata-Garcia M, Zurera Berjaga M, Moratiel Pellitero A, Gascon Ruiz M, Sesma Goñi A, Cruellas M, Ocáriz M, Alonso Marin N, Ruiz Moreno I, Goas Gomez A, Marti Pi M, Quilez E, Lastra R, Alvarez M, Torres I, Vinuesa Hernando JM, Camacho Fuentes C, Lambea J. Subclassification of the intermediate-risk group in patients with advanced renal cell carcinoma. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e16537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16537 Background: Renal cell carcinoma (RCC) have low prevalence but it incidence is increasing. For a correct therapeutic approach, it is important to carry out a correct prognostic stratification. Several prognostication systems have been proposed. One of the most commonly used is the one developed by Heng. It is based on IMDC database. This classification includes six prognostic factors (hemoglobin, neutrohils, platelets, serum calcium, Karnosky Performance Status and time from diagnosis to initiaton treatment) to divide patients into three gorups. The relevance of IMDC prognostic criterio, in the era of immunotherapy, remains to be established. In the absence of alternative criteria, these prognostication system continue to be used. A great prognostic disparity has been observed in the intermediate prognosis group. This raises the need to divide this group into two. Thus, patients included in it would be better selected. Methods: Observational, single-center, retrospective study, based on a cohort of 107 patients with advanced RCC, recruited from January 2006 to December 2019. Main objective: Evaluate whether survival of patients with intermediate prognosis (treated with antiangiogenic in first-line) is different depending on the presence of one or two prognostic factors. Descriptive and survival analysis (OS and PFS) were performed. In addition, the influence of prognostic factors on OS and PFS were compared using the log-rank test and Cox regression. Results: In the overall population, median overall survival (OS) was 26.86 months (95% CI: 21.09-32.63) and median PFS was 18.41 months (95% CI: 14.02-22.79). Median OS were, in favorable-risk 42.24 months (95% CI: 29.62-54.62), in intermediate-risk 27,24 (95% CI: 19.44-35-03) and in poor-risk 8.00 (95% CI: 4.54-11.45). Median PFS were in favorable-risk 30.53 months (95% CI:20.92-40.13), in intermediate-risk 17,16 (95% CI:11.54-22.78) and poor-risk 6.13 (95% CI:3.02-9.25). Median OS and PFS, in patients with intermediate-risk, with a single risk factor were 33.79 (95% CI 23.17-44.41) and 20.97 months (95% CI 13.35-28.59), compared to 14.88 (95% CI 8.80-20.95) and 10.59 months (95% CI 4.87-16.32) in those with two risk factors. The results were statistically significant in OS (p = 0.01) and PFS (p = 0.037). Conclusions: The differences in median OS and PFS, within the intermediate prognosis group (1 or 2 RF), confirm the existence of two subgroups of patients. Patients with 1 RF are similar to those with favorable-risk. These results are important since, the presence of 1 or 2 RF, would condition the choice of TKIs as part of the first-line treatment combination. More studies are needed to better subclassify the intermediate risk group when optimizing the best treatments for each patient.
Collapse
Affiliation(s)
- Maria Zapata-Garcia
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | | | | | - Marta Gascon Ruiz
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Andrea Sesma Goñi
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Mara Cruellas
- Medical Oncology Department, University Hospital Vall d´Hebron and Vall d´Hebron Institute of Oncology, Barcelona, Spain
| | - Maitane Ocáriz
- Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | | | - Ines Ruiz Moreno
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Ana Goas Gomez
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Maria Marti Pi
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Elisa Quilez
- Department of Medical Oncology, Hospital Clínico Lozano Blesa, Zaragoza, Spain
| | - Rodrigo Lastra
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Maria Alvarez
- Department of Medical Oncology, Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | - Irene Torres
- Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain
| | | | | | - Julio Lambea
- Department of Medical Oncology, Hospital Clínico Lozano Blesa, Zaragoza, Spain
| |
Collapse
|
7
|
Zucali PA, Ruiz MG, Giovannetti E, Destro A, Varella-Garcia M, Floor K, Ceresoli GL, Rodriguez JA, Garassino I, Comoglio P, Roncalli M, Santoro A, Giaccone G. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008; 19:1605-12. [PMID: 18467317 DOI: 10.1093/annonc/mdn240] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Approximately 10% of unselected non-small-cell lung cancer (NSCLC) patients responded to the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, resistance mechanisms are not well understood. We evaluated several potential biological markers of intrinsic EGFR-TKIs-resistance in NSCLC. MATERIALS AND METHODS pAKT, pERK, cSRC, E-cadherin, cMET[pY1003], cMET[pY1230/1234/1235], and cMET[pY1349] immunohistochemistry, cMET FISH analysis, and EGFR-, KRAS-, and cMET mutation analysis were carried out on tumor samples from 51 gefitinib-treated NSCLC patients. Biological parameters and survival end points were compared by univariate and multivariate analyses. cMET expression was also investigated in two additional series of patients. The in vitro antiproliferative activity of gefitinib alone or in combination with hepatocyte growth factor and the cMET antibody DN-30 was assessed in NSCLC cells. RESULTS EGFR19 deletion and pAKT expression were significantly associated with response (P < 0.0001) and longer time to progression (TTP) (P = 0.007), respectively. Strong cMET[pY1003] membrane immunoreactivity was expressed in 6% of 149 tumors analyzed and was significantly associated with progressive disease (P = 0.019) and shorter TTP (P = 0.041). In vitro, the DN-30 combination synergistically (CI < 1) enhanced gefitinib-induced growth inhibition in all cMET[pY1003]-expressing cell lines studied. CONCLUSIONS Activated cMET[pY1003] appears to be a marker of primary gefitinib resistance in NSCLC patients. cMET may be a target in treatment of NSCLC.
Collapse
Affiliation(s)
- P A Zucali
- Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Porras MC, Bonilla BC, Gómez EP, Ruiz MG. Dalteparin-induced extremity hematoma complicated by probable compartment syndrome. Ann Pharmacother 2001; 35:643-5. [PMID: 11346074 DOI: 10.1345/aph.10198] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|